Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

Notification of Full Year Results Date
RNS
RNS Number : 9190X
Clinigen Group plc
03 September 2015

3 September 2015



Notification of Full Year Results Date

Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its full year results for the year ended 30 June 2015 on Tuesday, 22 September 2015.



A group analyst briefing will be held at 9:30am on Tuesday, 22 September 2015 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.



Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email clinigen@instinctif.com to register

New alliance with Cumberland Pharmaceuticals
RNS
RNS Number : 3074Z
Clinigen Group plc
17 September 2015

17 September 2015



Clinigen Group signs strategic alliance with Cumberland Pharmaceuticals



Partnership strengthens Clinigen's global footprint

and gives Cumberland Pharmaceuticals access to new international markets



Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, has agreed to a strategic alliance with Cumberland Pharmaceuticals Inc. ('Cumberland', NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care. The alliance will combine Clinigen's and Cumberland's respective strengths, expertise and geographical footprints to maximize the commercial potential of future products.



As part of Clinigen's continuing strategy to extend its global presence, this collaboration will build on Clinigen's existing North American relationships by providing complementary support from Cumberland in the development, marketing, promotion and distribution of future products in the US.



Clinigen will be responsible for the marketing, promotion, distribution and sale of selected Cumberland pharmaceutical products, enabling Cumberland to use Clinigen's strong international reach to enter in to new markets outside of the US.



Peter George, CEO of Clinigen Group plc, said:

"A key strategic initiative this year has been to develop our Group's global distribution footprint. The US is a particular area of focus where we are looking to initiate a long term strategic partnership and Cumberland was a natural fit as a partner. Working together is a logical move for both companies as we will mutually benefit from each other's distribution expertise and capabilities in our respective regions."



AJ Kazimi, Chairman and CEO of Cumberland, added:

"This alliance with Clinigen creates a new growth driver for both companies that builds on our strengths. We look forward to working closely with Clinigen to bring its future products to patients in the US through our established commercial infrastructure. In turn, our products will gain access to new markets in other parts of the world."



Clinigen is focused on delivering the right drug to the right patient at the right time by providing medicines to patients with high unmet needs through clinical trials, licensed and ethically unlicensed supply. As part of this it acquires and revitalizes essential niche medicines to ensure pharmacists and doctors can continue to use the treatments their patients rely on and the business is always looking for new products to develop the pipeline.



Cumberland Pharmaceuticals acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. The company focuses on underserved niche markets in the US and currently markets five FDA approved products. These products include Acetadote® (acetylcysteine) injection for the treatment of acetaminophen poisoning and Vaprisol® (conivaptan) injection, for the treatment of hyponatremia. Cumberland also has a development pipeline with candidates in Phase II studies.



-Ends-

Final results - Tues 22 Sept

Good results and heading back towards the highs. Some good business alliances being formed too.

New MA program with Neuraltus Pharmaceuticals
RNS
RNS Number : 5825Z
Clinigen Group plc
21 September 2015

21 September 2015



Clinigen Group and Neuraltus Pharmaceuticals Announce Partnership to Initiate a Managed Access Program for Investigational ALS Therapy in Europe

Clinigen Group plc's ('Clinigen' or the 'Group', AIM: CLIN) Idis Managed Access (MA) division and Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of drugs to treat neurodegenerative diseases, announced today that the companies are partnering to initiate a Managed Access program for NP001, Neuraltus' investigational therapy for amyotrophic lateral sclerosis (ALS). The partnership makes the Managed Access program immediately available in selected European countries and is expected to gradually expand over the next year.



ALS, or Lou Gehrig's disease, is a rare and fatal neurodegenerative disease characterized by the degeneration of motor neurons in the spinal cord and brain. There are approximately 400,000 ALS patients worldwide, including 50,000 patients in Europe. Most patients and physicians report only modest slowing of ALS progression from existing treatments for ALS, underscoring the need for new and effective drug therapy.



"By partnering with companies like Neuraltus, Idis Managed Access plays a vital role in providing ethical access to unapproved medicines, like NP001, for patients with unmet medical needs," said Simon Estcourt, Managing Director, Idis Managed Access, Clinigen Group. "Our global regulatory and logistical expertise mean that we can deliver a fast and efficient response to physician inquiries. We look forward to working with both Neuraltus and the ALS community, to help patients in Europe who have no other available treatment options."



"Managed Access programs are about giving patients timely access to potential new therapies for devastating diseases, before the therapies are approved for general use," said Rich Casey, President and Chief Executive Officer at Neuraltus Pharmaceuticals, Inc. "We have received numerous inquiries from physicians, patients and their families regarding access to and inclusion in clinical studies for NP001. The planned Phase 2 study in the United States, coupled with our ability to provide NP001 to qualifying patients under a Managed Access program in Europe, underscores our commitment to the ALS community."



Access to NP001 will be provided by Idis MA to individual ALS patients who meet the established eligibility criteria via a regulatory compliant mechanism, following a physician request. European healthcare professionals can obtain details about the NP001 Managed Access program by calling +44 (0)1932 824 123 or via email at global@idispharma.com. Additional information can also be found on Neuraltus' website.



- Ends -

7% fall today - Director's dealings

07 Oct 2015 Clinigen Group Peter Allen 91,464 0 0
07 Oct 2015 Clinigen Group Peter Allen 91,464 685 626,528
07 Oct 2015 Clinigen Group Peter George 825,556 0 0
07 Oct 2015 Clinigen Group Peter George 825,556 685 5,655,059
07 Oct 2015 Clinigen Group Robin Sibson 1,000,000 685 6,850,000
07 Oct 2015 Clinigen Group Shaun Chilton 412,778 0 0
07 Oct 2015 Clinigen Group Shaun Chilton 412,778 685 2,827,52

Looks overdone, on director sales. Hopefully will hold the gains today.

So the gains didn't last long, back to the 200 day moving average. I took my profits out not so long ago but still running my initial outlay, which might also be coming out very soon.

Is that another "knifecatcher"?

I don't believe so, the business is doing well but when the CFO realises £6m...
You could also argue that a good price to get in at this level.

Some useful reasons:
Is now on a dowtrend
I do not like shares on a forward PE of 15 though is on a good growth path and although it has come down a lot recently is still on a prospective of 20
There is always a "cat bounce " but the trend is your friend also.
take it or leave it the choice is yours @ 623.25p

This isn't a dead cat though! Could easily put the money somewhere else, plenty on the watch list.

Took my last tranche out to put into metals. Still like the stock though and will be watching. Suspect this is just a correction on director sales.

AGM Statement
RNS
RNS Number : 4909D
Clinigen Group plc
27 October 2015

27 October 2015

AGM Statement

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global specialty pharmaceuticals business, is holding its Annual General Meeting ("AGM") at 10.00am today at Instinctif Partners' offices, 65 Gresham Street, London EC2 7NQ.

At the meeting Peter Allen, Clinigen's Chairman, and Peter George, Group Chief Executive Officer, will cover the following areas:

This has been a strategically transformational year for the Group. During the year, Clinigen has doubled the size of the business, strengthened its global capabilities, become the global market leader in the ethical supply of unlicensed medicines and continued the revitalization of its speciality products portfolio.

Through the acquisition of Idis, the Group has extended its unique, synergistic business model and created a better balanced portfolio of businesses. Clinigen is now the market leader in the $5+ billion unlicensed medicine supply sector and the $2 billion clinical trial supply market. The proposed acquisition of Link, due to complete shortly, will also substantially broaden the Group's international distribution footprint across the AAA region - Asia, Africa and Australasia.

As reported at Clinigen's full year results in September, all of its newer specialty pharma assets - Cardioxane, Savene and Ethyol - continue to progress to plan. The lifting of the EMA Article 31 referral for Cardioxane also remains on track.

Having completed the CFO handover period, described previously, Robin Sibson will step down from the role of CFO after the AGM and Martin Abell will now assume that role with immediate effect. The Board welcomes Martin and thanks Robin for the important role that he has played in the success and development of the Group. Robin will continue to work with the Group in his new role as a Non-Executive Director of Clinigen.

Clinigen's strong financial performance demonstrates its strengthened international position in growing markets. The Group is on track in advancing its underlying philosophy of getting the right drug to the right patient at the right time, regardless of where they are in the world.



-Ends-

products-the-priority-for-clinigen-says-deputy-chief-after-transformational-2015

Half yearly report


HIGHLIGHTS

§ Adjusted gross profit* doubled, reflecting change in scale following acquisitions

§ Adjusted EPS* up 21% to 15.1p (2014: 12.5p)

§ Interim dividend up 18% to 1.3p (2014: 1.1p)

§ £22.1m cash generated from operations, up 96%

§ Revitalisation of newer products has driven strong Specialty Pharmaceuticals performance

§ All commercial and most of operational integration complete for Idis

§ Link Healthcare acquisition builds global footprint, adding capability in Australia, Africa and Asia

§ Further extension of Dexrazoxane product line with the acquisition of Totect from Biocodex, opening up the US market for Clinigen (see separate announcement for further details)

§ Positioned for good growth in H2, in line with Board expectations

2 Mar Stifel 800.00 Buy
2 Mar Numis 916.00 Buy
2 Mar Peel Hunt 1,000.00 Buy

Trading statement Wed 20th

Trading update

RNS


RNS Number : 6704E

Clinigen Group plc

20 July 2016




20 July 2016





Year end trading update



Strong second half performance completes transformational year for Clinigen



Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, today provides a trading update for the 12 months ended 30 June 2016.



Highlights



· Revenue and gross profit up 87% and 90% respectively driven by acquisitions and organic growth*

· Significant step up in performance in H2, driven by Clinical Trial Services, Specialty Pharma and Managed Access

· Specialty Pharma portfolio enhanced by acquisition of Totect and product line extension for Foscavir

· Integration of Idis and Link acquisitions substantially complete



Peter George, Chief Executive Officer of Clinigen Group said:



"The integration of Idis and Link Healthcare has transformed the Group into the global market leader in the management and supply of both unlicensed and Clinical Trial medicines.



"We had a strong second half performance, completing a transformational year. The newer products in our Specialty Pharma portfolio are making good progress, demonstrating the effectiveness of our revitalisation model and we saw another excellent year in the Clinical Trial Services division.



"We are entering the new financial year in an excellent position, having delivered on our key strategic objectives. A major focus for FY17 will be to develop our Global Access on-demand unlicensed offering to hospital pharmacists, an exciting opportunity for the Group.



"Our priorities now are to capitalise on our market leader positions, drive organic growth and continue to progress the revitalisation of our products."





Group performance



Revenue and gross profit increased by 87% and 90% respectively versus last year. The growth has been delivered by a combination of the acquisitions of Idis in April 2015 and Link Healthcare in October 2015, as well as organic growth in the underlying business.



The Specialty Pharma division, representing 31% of Group gross profits, achieved good growth. Foscavir performed as expected during the year and the Foscarnet in bags product line extension, announced in May 2016, enhances the product and is expected to extend its lifecycle.



The newer products, Cardioxane, Savene and Ethyol made excellent progress in the year, collectively increasing gross profits by over 30%. The expansion of the Dexrazoxane franchise saw the addition of Totect in March 2016. Totect provides an important entry into the US and is expected to start providing revenues in the second half of FY17.



The Managed Access division, representing 26% of Group gross profits, had a good year after taking account of a complex integration following the Idis acquisition. As expected, the start of a number of important new programs resulted in a stronger performance in the second half, positioning the division well going into FY17.



The Global Access division, representing 14% of Group gross profits, recorded gross profits marginally ahead of last year. This is after taking account of the planned disposal of the low margin commercial contract discussed following the acquisition of Idis. The Group's market leading positions in the Managed Access space and the local capability and expertise provided by the Link acquisition, will enable us to capitalise on the considerable long term international opportunity in the 'on-demand' unlicensed medicine market.



The Clinical Trial Services division, representing 19% of Group gross profits in the year, delivered excellent growth combining strong activity within its existing customer portfolio with some important new customer wins through the year. Good levels of clinical trial activity, a widening customer base and the continued roll out of our value added services are expected to drive further strong growth in FY17.



Link Healthcare, representing 10% of Group gross profits in the year, had a solid underlying performance with the strongest growth coming from the developing Asian business. Whilst reported results for Link Healthcare have been affected this year by the depreciation of local currencies, particularly in South Africa, these effects are expected to reverse in the current financial year following the recent depreciation in sterling.



Integration of acquisitions



The integration of both the Idis business and Link Healthcare is substantially complete. Acquisition and integration costs relating to Idis and Link will be shown as non-underlying costs.



Net debt



Net debt has decreased from £76.2 million as at 30 June 2015 to around £67 million as at 30 June 2016 with the cash consideration for the Link Healthcare acquisition and the product acquisitions funded from the free cash flow of the Group.





EU Referendum



Brexit is not expected to have any adverse effects on the Group in the short term. Whilst the outcomes are not yet clear, the Group's flexible operating model, the team's deep understanding of multinational regulatory process and with around 85% of revenues being from International markets, it is expected that any medium to long term implications will be manageable.



Outlook



Overall the Group has traded in line with the Board's expectations and all divisions are well positioned for good growth next year.



The Group expects to publish its final results for the year ended 30 June 2016 on Wednesday 28 September 2016.



*Revenue and gross profit growth rates include Clinigen's share of the South Africa Joint Venture and exclude the impact of the release of the fair valuation of inventory acquired with Idis and Link Healthcare. Under IFRS, the Joint Venture is excluded from revenue, gross profit and profit before tax and the Group's share of the Joint Venture's profit after tax is included in the Profit and Loss Account as 'other income'. The release of the fair value element of inventories is included in the non-underlying costs of the Group.



- Ends -

20 Jul Stifel 800.00 Buy
20 Jul Numis 916.00 Buy
20 Jul Peel Hunt 1,000.00 Buy